Skip to main content

Table 2 Clinical characteristics and HCRU of patients with CRSwNP, stratified by surgery and biologic use

From: Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study

 

All patients

All patients

Sinus surgery

No sinus surgery

N = 5997

Biologic use

N = 642

No biologic use

N = 5355

P-value

N = 55

Biologic use

N = 420

No biologic use

P-value

N = 587

Biologic use

N = 4935

No biologic use

P-value

DCI [44, 45] mean (SD)

0.8 (1.1)

1.2 (1.0)

0.7 (1.1)

 < 0.001

1 (0.7)

0.8 (1.2)

0.143

1.2 (1.0)

0.7 (1.1)

 < 0.001

Clinical conditions, n (%)

          

Asthma

2446 (40.8)

572 (89.1)

1874 (35.0)

 < 0.001

44 (80.0)

148 (35.2)

 < 0.001

528 (89.9)

1726 (35.0)

 < 0.001

Allergic rhinitis

3713 (61.9)

502 (78.2)

3211 (60.0)

 < 0.001

46 (83.6)

262 (62.4)

0.002

456 (77.7)

2949 (59.8)

 < 0.001

Atopic dermatitis

76 (1.3)

23 (3.6)

53 (1.0)

< 0.001

0 (0)

7 (1.7)

1

23 (3.9)

46 (0.9)

 < 0.001

Chronic idiopathic urticaria

49 (0.8)

28 (4.4)

21 (0.4)

 < 0.001

3 (5.5)

1 (0.2)

0.005

25 (4.3)

20 (0.4)

 < 0.001

COPD

451 (7.5)

79 (12.3)

372 (6.9)

 < 0.001

9 (16.4)

36 (8.6)

0.064

70 (11.9)

336 (6.8)

 < 0.001

Diabetes

573 (9.6)

60 (9.3)

513 (9.6)

0.849

4 (7.3)

44 (10.5)

0.459

56 (9.5)

469 (9.5)

0.977

Eosinophilic esophagitis

26 (0.4)

5 (0.8)

21 (0.4)

0.191

0 (0)

0 (0)

1

5 (0.9)

21 (0.4)

0.189

EGPA

12 (0.2)

9 (1.4)

3 (0.1)

< 0.001

0 (0)

0 (0)

1

9 (1.5)

3 (0.1)

 < 0.001

GERD

992 (16.5)

149 (23.2)

843 (15.7)

< 0.001

14 (25.5)

69 (16.4)

0.097

135 (23.0)

774 (15.7)

 < 0.001

Hypertension

1816 (30.3)

190 (29.6)

1626 (30.4)

0.689

11 (20.0)

121 (28.8)

0.170

179 (30.5)

1505 (30.5)

0.999

Malignant neoplasm of respiratory and intrathoracic organs

25 (0.4)

0 (0)

25 (0.5)

0.103

0 (0)

4 (1.0)

1

0 (0)

21 (0.4)

0.158

Respiratory infections

1566 (26.1)

196 (30.5)

1370 (25.6)

0.007

19 (34.5)

129 (30.7)

0.564

177 (30.2)

1241 (25.1)

0.009

Rheumatoid arthritis

55 (0.9)

3 (0.5)

52 (1.0)

0.206

0 (0)

4 (1.0)

1

3 (0.5)

48 (1.0)

0.269

Rhinosinusitis (acute)

2034 (33.9)

233 (36.3)

1801 (33.6)

 0.178

24 (43.6)

171 (40.7)

0.679

209 (35.6)

1630 (33.0)

0.211

Rhinosinusitis (chronic)

4588 (76.5)

515 (80.2)

4073 (76.1)

 0.019

48 (87.3)

359 (85.5)

0.721

467 (79.6)

3714 (75.3)

0.022

SLE

13 (0.2)

2 (0.3)

11 (0.2)

 0.642

0 (0)

0 (0)

1

2 (0.3)

11 (0.2)

0.641

Number of comorbid conditions (among all listed above), n (%)

          

0

155 (2.6)

1 (0.2)

154 (2.9)

 < 0.001

0 (0)

2 (0.5)

0.023

1 (0.2)

152 (3.1)

 < 0.001

1

760 (12.7)

18 (2.8)

742 (13.9)

 

1 (1.8)

57 (13.6)

 

17 (2.9)

685 (13.9)

 

2

1357 (22.6)

79 (12.3)

1278 (23.9)

 

8 (14.5)

81 (19.3)

 

71 (12.1)

1197 (24.3)

 

 ≥ 3

3725 (62.1)

544 (84.7)

3181 (59.4)

 

46 (83.6)

280 (66.7)

 

498 (84.8)

2901 (58.8)

 

Number of common respiratory conditions,* n (%)

          

0

289 (4.8)

2 (0.3)

287 (5.4)

 < 0.001

0 (0)

7 (1.7)

0.001

2 (0.3)

280 (5.7)

 < 0.001

1

1143 (19.1)

31 (4.8)

1112 (20.8)

 

3 (5.5)

75 (17.9)

 

28 (4.8)

1037 (21.0)

 

2

1804 (30.1)

136 (21.2)

1668 (31.1)

 

9 (16.4)

129 (30.7)

 

127 (21.6)

1539 (31.2)

 

 ≥ 3

2761 (46.0)

473 (73.7)

2288 (42.7)

 

43 (78.2)

209 (49.8)

 

430 (73.3)

2079 (42.1)

 

Asthma exacerbations, n (%)†

          

Medical claim for asthma

2446 (40.8)

572 (89.1)

1874 (35.0)

 < 0.001

44 (80.0)

148 (35.2)

 < 0.001

528 (89.9)

1726 (35.0)

 < 0.001

 ≥ 1 asthma exacerbation

487 (19.9)

142 (24.8)

345 (18.4)

0.001

14 (31.8)

33 (22.3)

0.197

128 (24.2)

312 (18.1)

0.002

Number of exacerbations

          

1

391 (80.3)

104 (73.2)

287 (83.2)

0.048

8 (57.1)

19 (57.6)

0.915

96 (75.0)

268 (85.9)

0.012

2

67 (13.8)

24 (16.9)

43 (12.5)

 

6 (42.9)

11 (33.3)

 

18 (14.1)

32 (10.3)

 

3

17 (3.5)

7 (4.9)

10 (2.9)

 

0 (0)

1 (3.0)

 

7 (5.5)

9 (2.9)

 

4

7 (1.4)

4 (2.8)

3 (0.9)

 

0 (0)

2 (6.1)

 

4 (3.1)

1 (0.3)

 

 ≥ 5

5 (1.0)

3 (2.1)

2 (0.6)

 

0 (0)

0 (0)

 

3 (2.3)

2 (0.6)

 

 ≥ 2 asthma exacerbations

96 (19.7)

38 (26.8)

58 (16.8)

0.012

6 (42.9)

14 (42.4)

0.978

32 (25.0)

44 (14.1)

0.006

CRSwNP-related HCRU, n (%)

Endoscopy services

4358 (72.7)

388 (60.4)

3970 (74.1)

 < 0.001

39 (70.9)

314 (74.8)

0.539

349 (59.5)

3656 (74.1)

 < 0.001

Sinus CT scan services

1337 (22.3)

86 (13.4)

1251 (23.4)

 < 0.001

14 (25.5)

147 (35.0)

0.16

72 (12.3)

1104 (22.4)

 < 0.001

Office-administered CRSwNP-related drug services

328 (5.5)

207 (32.2)

121 (2.3)

 < 0.001

17 (30.9)

10 (2.4)

 < 0.001

190 (32.4)

111 (2.2)

 < 0.001

Outpatient pharmacy prescriptions

5373 (89.6)

616 (96.0)

4757 (88.8)

 < 0.001

53 (96.4)

391 (93.1)

0.561

563 (95.9)

4366 (88.5)

 < 0.001

  1. Clinical characteristics and healthcare resource utilization were measured on the earliest CRSwNP diagnosis date during the patient identification period (6/30/2018–6/30/2019). Patients were stratified by biologic and non-biologic use during the observation period (7/1/2019–6/30/2020). P-values in bold signify P < 0.05 for comparison within individual categories for biologic versus non-biologic use in each cohort (i.e., all patients, sinus surgery, no sinus surgery)
  2. *Common respiratory conditions include chronic rhinosinusitus, allergic rhinitis, asthma, acute sinusitis, and respiratory infections; †asthma exacerbations were identified if either of the following criteria were met: outpatient or emergency department visit with a diagnosis of asthma AND ≤ 1 dispensing of systemic corticosteroids ± 5 days after the encounter, or inpatient hospital admissions with a diagnosis of asthma as a primary diagnosis. An exacerbation recorded within 14 days of a previous exacerbation was counted with the previous exacerbation as part of a single exacerbation episode
  3. COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; CT, computed tomography; DCI, Deyo-Charlson Comorbidity Index; EGPA, eosinophilic granulomatosis with polyangiitis; GERD, gastroesophageal reflux disease; HCRU, healthcare resource utilization; SD, standard deviation; SLE, systemic lupus erythematosus
Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us